Cancer immunotherapy: Moving beyond current vaccines

Steven A. Rosenberg, James C. Yang, Nicholas P. Restifo

Research output: Contribution to journalArticle

Abstract

Great progress has been made in the field of tumor immunology in the past decade, but optimism about the clinical application of currently available cancer vaccine approaches is based more on surrogate endpoints than on clinical tumor regression. In our cancer vaccine trials of 440 patients, the objective response rate was low (2.6%), and comparable to the results obtained by others. We consider here results in cancer vaccine trials and highlight alternate strategies that mediate cancer regression in preclinical and clinical models.

Original languageEnglish (US)
Pages (from-to)909-915
Number of pages7
JournalNature Medicine
Volume10
Issue number9
DOIs
StatePublished - Sep 2004
Externally publishedYes

Fingerprint

Cancer Vaccines
Immunotherapy
Vaccines
Tumors
Immunology
Neoplasms
Allergy and Immunology
Biomarkers

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Rosenberg, S. A., Yang, J. C., & Restifo, N. P. (2004). Cancer immunotherapy: Moving beyond current vaccines. Nature Medicine, 10(9), 909-915. https://doi.org/10.1038/nm1100

Cancer immunotherapy : Moving beyond current vaccines. / Rosenberg, Steven A.; Yang, James C.; Restifo, Nicholas P.

In: Nature Medicine, Vol. 10, No. 9, 09.2004, p. 909-915.

Research output: Contribution to journalArticle

Rosenberg, SA, Yang, JC & Restifo, NP 2004, 'Cancer immunotherapy: Moving beyond current vaccines', Nature Medicine, vol. 10, no. 9, pp. 909-915. https://doi.org/10.1038/nm1100
Rosenberg, Steven A. ; Yang, James C. ; Restifo, Nicholas P. / Cancer immunotherapy : Moving beyond current vaccines. In: Nature Medicine. 2004 ; Vol. 10, No. 9. pp. 909-915.
@article{cb2469775ca54ef2a7e0084ba9a69422,
title = "Cancer immunotherapy: Moving beyond current vaccines",
abstract = "Great progress has been made in the field of tumor immunology in the past decade, but optimism about the clinical application of currently available cancer vaccine approaches is based more on surrogate endpoints than on clinical tumor regression. In our cancer vaccine trials of 440 patients, the objective response rate was low (2.6{\%}), and comparable to the results obtained by others. We consider here results in cancer vaccine trials and highlight alternate strategies that mediate cancer regression in preclinical and clinical models.",
author = "Rosenberg, {Steven A.} and Yang, {James C.} and Restifo, {Nicholas P.}",
year = "2004",
month = "9",
doi = "10.1038/nm1100",
language = "English (US)",
volume = "10",
pages = "909--915",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Cancer immunotherapy

T2 - Moving beyond current vaccines

AU - Rosenberg, Steven A.

AU - Yang, James C.

AU - Restifo, Nicholas P.

PY - 2004/9

Y1 - 2004/9

N2 - Great progress has been made in the field of tumor immunology in the past decade, but optimism about the clinical application of currently available cancer vaccine approaches is based more on surrogate endpoints than on clinical tumor regression. In our cancer vaccine trials of 440 patients, the objective response rate was low (2.6%), and comparable to the results obtained by others. We consider here results in cancer vaccine trials and highlight alternate strategies that mediate cancer regression in preclinical and clinical models.

AB - Great progress has been made in the field of tumor immunology in the past decade, but optimism about the clinical application of currently available cancer vaccine approaches is based more on surrogate endpoints than on clinical tumor regression. In our cancer vaccine trials of 440 patients, the objective response rate was low (2.6%), and comparable to the results obtained by others. We consider here results in cancer vaccine trials and highlight alternate strategies that mediate cancer regression in preclinical and clinical models.

UR - http://www.scopus.com/inward/record.url?scp=4644324025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644324025&partnerID=8YFLogxK

U2 - 10.1038/nm1100

DO - 10.1038/nm1100

M3 - Article

C2 - 15340416

AN - SCOPUS:4644324025

VL - 10

SP - 909

EP - 915

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 9

ER -